This study is testing a new medicine called lunsekimig for adults with Chronic Obstructive Pulmonary Disease (COPD). COPD is a lung disease that makes it hard to breathe. The study will see if lunsekimig is safe, works well, and is easy to take compared to a placebo, which is a pretend medicine that doesn’t do anything. Participants will get a shot under their skin, called a subcutaneous (SC) treatment, for about 48 weeks. The study is 60 weeks long (about 1 year and 2 months) and has three parts: - Screening: Up to 4 weeks to check if you can join the study. - Treatment: 48 weeks of taking the study medicine or placebo. - Follow-up: 8 weeks to see how you are doing after treatment ends. Key Points:

• The study lasts for up to 60 weeks.
• It involves regular visits and treatments over 48 weeks.
• Participants need to be between 40 to 80 years old with certain health conditions.